Navigation Links
Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma

LONDON, Feb. 10 /PRNewswire/ -- Microdosing or Phase 0 clinical testing has been gaining acceptance and might become an imperative phase of the drug development process in the years to come. The emergence of niche capability providers in preclinical testing and technology dependence is also expected to result in numerous partnerships and alliances, fuelling growth opportunities in this sector.


"There is every reason to believe that the solution for faster screening of candidates and increasing pressure on costs is gaining momentum in the right direction," notes Frost & Sullivan ( Senior Research Analyst V. Sriram. "The compelling advantages of microdosing present it as a potential remedy for big pharma's maladies regarding declining returns from investments in drug development."

Alliances between contract research organisations (CROs) in the U.S. and Europe have not historically been common. This is due to several factors including the industry's strong growth and relatively low technology demands for clinical testing. However, developments in microdosing should see a number of opportunities being investigated.

Consolidation within the CRO space has led to concerns over the quality of service and attention to detail. Companies must however ensure the quality of their services to maintain their bargaining power with the pharmaceutical companies.

"CROs face the challenge of competitively aligning their services to meet customer needs in order to overcome the threat of losing their stronghold and loyalty," comments Sriram.

Developing the technological know-how and expertise on niche capabilities will help CROs retain their client base. This can be achieved in-house or by partnerships with pioneers in the provision of niche capability, allowing for the creation of a one-stop shop solution.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the study, Strategic Analysis of Opportunities in the CRO Market - Phase 0, then send an e-mail to Katja Feick, Corporate Communications, at Please include your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

Strategic Analysis of Opportunities in the CRO Market - Phase 0 is part of the Pharmaceuticals & Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market Outlook, European Vaccines Market, U.S. Contract Research Outsourcing Markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit

Strategic Analysis of Opportunities in the CRO Market - Phase 0


    Katja Feick
    Corporate Communications - Europe
    P: +49 (0) 69 77 0 33 43

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award
2. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
3. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
4. Signalife Wins Second Frost & Sullivan Technology Award
5. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
6. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):